Posted on 13/10/2009 in Pharmaceutical Company Product News Ranbaxy and Daiichi Sankyo have created a new subsidiary aimed at the generic drugs market, it has emerged.
Ranbaxy and Daiichi Sankyo have signed an agreement that will allow the former company to commercialise the product portfolio of its new partner.
Through the newly-created subsidiary Ranbaxy Mexico SA de CV, the firms will bring the products to a new market, marking the first time that they have cooperated in this area.
It will allow the two firms to leverage their respective strengths in the dominant prescription segment and commence their expansion in the generics market.
"The creation of a Daiichi Sankyo Division within Ranbaxy - Mexico marks our first endeavour in creating a dedicated marketing arm for Daiichi Sankyo's portfolio of innovator products," said Atul Sobti, chief executive and managing director of Ranbaxy.
Last month, Ranbaxy and Daiichi Sankyo jointly announced that the marketing of Evista will be handled by the Ranbaxy subsidiary Terapia.
At the time, Takashi Shoda, president of Daiichi Sankyo, said that the two firms were hoping to explore further partnerships in future.
Other news stories from 13/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
